Hepagene Therapeutics

Hepagene Therapeutics, Inc. is a clinical-stage drug discovery and development company focused on creating innovative medicines to combat liver diseases and other life-threatening conditions. The company primarily targets non-alcoholic steatohepatitis (NASH), chronic Hepatitis B infection (HBV), and Hepatocellular Carcinoma. Hepagene operates in the biopharmaceutical market, serving patients who suffer from these severe liver conditions. The business model revolves around the discovery, development, and delivery of new therapeutic drugs, with revenue generated through the successful commercialization of these treatments. The company recently announced the dosing of the first healthy subject in a Phase I study of HPG1860, a promising drug candidate for NASH.

Keywords: NASH, HBV, Hepatocellular Carcinoma, drug discovery, clinical-stage, biopharmaceutical, liver diseases, innovative medicines, Phase I study, HPG1860.